Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-M in Advanced Solid Tumors
NCT07409766Phase 1Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jan 2026
- Primary completion
- Dec 2028
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of CAR-M in solid tumor (advanced stage) (2 cohorts), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Incidence of Dose-Limiting Toxicities at 28 days, Incidence of Adverse Events at 24 months and 1 more. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
CAR-M
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07409766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07409766.